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ABSTRACT
Objectives: To examine secular and socioeconomic
changes in biological cardiovascular disease risk factor
and biomarker prevalences in the Scottish population.
This could contribute to an understanding of why the
decline in coronary heart disease mortality in Scotland
has recently stalled along with persistence of
associated socioeconomic inequalities.
Design: Cross-sectional surveys.
Setting: Scotland.
Participants: Scottish Health Surveys: 1995, 1998,
2003, 2008 and 2009 (6190, 6656, 5497, 4202 and
4964 respondents, respectively, aged 25e64 years).
Primary outcome measures: Gender-stratiﬁed, age-
standardised prevalences of obesity, hypertension,
hypercholesterolaemia and low high-density
lipoprotein cholesterol blood concentration as well as
elevated ﬁbrinogen and C reactive protein
concentrations according to education and social class
groupings. Inequalities were assessed using the slope
index of inequality, and time trends were assessed
using linear regression.
Results: The prevalence of obesity, including central
obesity, increased between 1995 and 2009 among
men and women, irrespective of socioeconomic
position. In 2009, the prevalence of obesity (deﬁned by
body mass index) was 29.8% (95% CI 27.9% to
31.7%) for men and 28.2% (26.3% to 30.2%) for
women. The proportion of individuals with
hypertension remained relatively unchanged between
1995 and 2008/2009, while the prevalence of
hypercholesterolaemia declined in men from 79.6%
(78.1% to 81.1%) to 63.8% (59.9% to 67.8%) and in
women from 74.1% (72.6% to 75.7%) to 66.3%
(62.6% to 70.0%). Socioeconomic inequalities
persisted over time among men and women for most
of the biomarkers and were particularly striking for the
anthropometric measures when stratiﬁed by
education.
Conclusions: If there are to be further declines in
coronary heart disease mortality and reduction in
associated inequalities, then there needs to be
a favourable step change in the prevalence of
cardiovascular disease risk factors. This may require
radical population-wide interventions.
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ARTICLE SUMMARY
Article focus
- In Scotland, as in other developed countries,
coronary heart disease mortality has substan-
tially declined over time.
- This decline may have slowed among younger
ages and there are still large socioeconomic
inequalities in mortality.
- Examination of the secular and socioeconomic
changes in biological cardiovascular disease risk
factor and biomarker prevalences in the Scottish
population.
Key messages
- In Scotland, over a 14-year period since 1995,
there has been a substantial increase in the
prevalence of obesity with a persistence of large
inequalities.
- At the same time, the prevalence of hypertension
has changed little, while that of hypercholester-
olaemia has declined, albeit from a very high
level. Inequalities were generally smaller and, in
the case of cholesterol in men, ill deﬁned.
- Such trends can only serve to curb any further
declines in coronary heart disease mortality and
maintain associated inequalities.
Strengths and limitations of this study
- This study utilised data from nationally repre-
sentative surveys conducted over a 14-year
period.
- Bias may have been introduced by declining survey
response levels. Differential non-response by the
socioeconomically disadvantaged may lead to an
underestimation of the magnitude of inequalities.
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Open Access ResearchINTRODUCTION
The rapid absolute decline in Scottish coronary heart
disease (CHD) mortality since the 1970s
1 has slowed
from 1994 onwards for individuals <55 years of age.
2
Such plateaus in CHD mortality rates have also been
identiﬁed in the USA, Australia and England.
3e5 Risk
factor reduction is believed to account for at least half of
the decline that has occurred, the remainder being
mainly ascribed to advancements in treatment.
6e8
There is a persistent socioeconomic gradient across
CHD mortality in many countries, and in some places,
inequalities may be widening.
2 9 Much of the excess
CHD associated with socioeconomic disadvantage can be
explained by the corresponding patterning in cardio-
vascular disease (CVD) risk factors.
10e12
In Scotland, over a 13-year period leading up to 2008,
there had been minimal decline in behavioural CVD risk
factors and no substantial change in socioeconomic
inequalities.
13 Of further concern is the increase in self-
reported diabetes and hypertension during this time. This
study investigates the socioeconomic patterning of bio-
logical CVD risk factors and markers that are intermediate
between behavioural risk factors and CHD, in Scotland
between 1995 and 2009. Our hypothesis was that there
would be stagnation in prevalence trends in these
biomarkers for CVD and that this might provide some
explanation for the worrying trends in CHD mortality.
METHODS
Survey method and sample
The 1995, 1998, 2003, 2008 and 2009 Scottish Health
Surveys (SHeSs) are cross-sectional nationally represen-
tative surveys reporting the health and health-related
behaviours (with emphasis on CVD) of people living in
private households in Scotland; details are described
elsewhere.
14e18 Brieﬂy, samples were selected using
a multistage, stratiﬁed, clustered probability sampling
design. Data were collected during two household visits:
ﬁrst by an interviewer and then by a nurse. During the
face-to-face interviews, information such as age, gender,
educational status and occupational social class was
ascertained. Bodyweight was measured to the nearest
100 g using electronic scales, an estimate was requested
from respondents that exceeded the scales’ upper limit
of 130 kg. Height was measured to the nearest milli-
metre using a stadiometer.
During the nurse visit, blood pressure measurements,
details of prescription drug use and non-fasting venous
blood samples, as well as waist and hip circumferences,
were obtained. The latter were measured using a tape
with an insertion buckle and recorded to the nearest
millimetre with at least two measurements combined to
provide a mean. The waist was deﬁned as the midpoint
between the lower rib and the upper margin of the iliac
crest. Hips were measured at the widest circumference
around the buttocks below the iliac crest.
Blood pressure readings were taken using an auto-
mated device with the informant in a seated position,
after a 5 min rest. Data used in this study are based on
the mean of the second and third readings of partici-
pants that had not eaten, smoked, drunk alcohol or
taken vigorous exercise in the 30 min preceding
measurement. The ﬁrst two surveys employed Dinamap
8100 monitors (Critikon, Tampa, Florida, USA), while
from 2003, Omron HEM 907 devices (Omron Health-
care, Kyoto, Japan) were used. Regression equations
generated from a calibration study were used to derive
predicted Omron readings from Dinamap readings.
15
The same laboratory conducted blood sample analyses
except for the 1995 survey. Total cholesterol serum
concentration was determined by a cholesterol oxidase
assay. In 1995 and 1998, high-density lipoprotein (HDL)
cholesterol serum concentration was estimated using the
cholesterol oxidase assay following PTA precipitation.
From 2003, a direct method was used for analysis. Serum
C reactive protein was estimated from 1998 onwards
using the N Latex CRP mono Immunoassay. Plasma
ﬁbrinogen concentration was estimated using a modiﬁ-
cation of the Clauss thrombin clotting method, again
from 1998 with different analysing equipment used from
2008.
The 2008 and 2009 surveys were part of a continuous
survey running until 2011; sample sizes were smaller
than in previous surveys and the nurse interview was
a subsample (tables 1 and 2). The main interview
response proportion declined from 81% in 1995 to 56%
in 2009. The surveys were age limited in 1995
(16e64 years) and in 1998 (2e74 years). Analyses were
restricted to individuals aged between 25 and 64 years at
the time of interview for all surveys. The lower limit was
adopted because educational achievement is believed to
be relatively stable by this age, while the 1995 survey
dictated the upper limit. To ensure nationally repre-
sentative data, the nurse examination subsamples from
2008 (n¼720) and 2009 (n¼762) were merged. Preg-
nant women were excluded from all measurements and
the blood sample collection.
Risk factors and risk markers
Biomarkers were dichotomised, using thresholds that
indicated increased risk of CVD, as follows: body mass
index (BMI; weight (kg) divided by height squared
(m
2)) with obesity deﬁned as $30 kg/m
21 9 ; gender-
speciﬁc deﬁnitions of excessive waist circumference
(WC) were $102 cm for men, $88 cm for women
19;
waistehip ratio (WHR; WC divided by hip circumfer-
ence) excess was deﬁned as $1 and $0.85 for men and
women, respectively
19; hypertension (uncontrolled) was
reported for those individuals with systolic pressure
$140 mm Hg or diastolic pressure $90 mm Hg, irre-
spective of treatment
20; hypercholesterolaemia was
deﬁned as a serum total cholesterol $5.0 mmol/l,
medication was ignored
21; high-risk HDL cholesterol
serum concentration was deﬁned by gender-speciﬁc
thresholds: <1.0 mmol/l for men and <1.2 mmol/l for
women
21; total cholesterol: HDL cholesterol ratio cut-off
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Cardiovascular biomarker patternsfor increased risk was 4.5, irrespective of medication; for
both ﬁbrinogen and C reactive protein values in the
highest quintile determined for each survey sample as
a whole, stratiﬁed by gender, were deﬁned increased risk.
Total cholesterol and hypertension were investigated
irrespective of drug treatment as this study was interested
in risk marker changes, whatever the cause.
Socioeconomic measures
Individual respondents’ Registrar General’s occupa-
tional social class was divided into seven categories I, II,
III non-manual, III manual, IV, V and others (including
armed forces/unknown). From 2003, the Registrar
General’s social class was not directly recorded, this
necessitated its derivation from the National Statistics
Socio-Economic Classiﬁcation (NS-SEC).
22 23 The
highest educational qualiﬁcation that respondents
achieved was divided into four levels: no qualiﬁcations,
level 1: age at end of compulsory schooling ¼16 years
from 1971, 15 years from 1947 and 14 years prior to 1947
(O grade, standard grade, GCSE or equivalent), level 2
(higher grade, A level, GSVQ advanced or equivalent
and HNC, HND, SVQ level 4 or 5 or equivalent) and
level 3 (ﬁrst degree, higher degree or professional
qualiﬁcations). Between each survey, there was slight
variation in the questions used to determine educational
attainment to reﬂect changes in the education system.
Statistical analyses
The prevalence of each risk factor was determined for
the period 1995e2008/2009 according to social class or
education; participants in the ‘other’ categories were
excluded (tables 1 and 2). Individuals with missing data
were excluded from affected analyses. Survey weights
were used to adjust for disproportionate sampling,
differing selection probabilities and differential non-
response. Nurse sample and blood sample weights were
available for the 2003 and 2008/2009 data sets. Gender-
stratiﬁed prevalences were age standardised (direct
method) to the European standard population using 5-
year age groups.
24 For each risk factor and survey year,
the slope index of inequality (SII), an absolute measure
of inequality, was estimated using the weighted least
squares method. The SII is the linear regression
Table 1 Characteristics of the 1995, 1998, 2003, 2008 and 2009 Scottish Health Surveys: interview samples restricted to
25e64-year old respondents (unweighted data)
Scottish Health Survey
1995 1998 2003 2008 2009
Sample size, n 6910 6656 5497 4202 4964
Mean age (SD) 43.3 (11.6) 43.8 (11.3) 45.3 (10.9) 46.0 (11.0) 45.6 (11.0)
Gender, n (%)
Male 3049 (44.1) 2969 (44.6) 2437 (44.3) 1839 (43.8) 2136 (43.0)
Female 3861 (55.9) 3687 (55.4) 3060 (55.7) 2363 (56.2) 2828 (57.0)
Ethnicity, n (%)
White 6852 (99.2) 6571 (98.7) 5357 (97.5) 4066 (96.8) 4819 (97.1)
Other 55 (0.8) 70 (1.1) 103 (1.9) 117 (2.8) 112 (2.3)
Missing 3 (0.0) 15 (0.2) 37 (0.7) 19 (0.5) 33 (0.7)
BMI, n (%)
<30 kg/m
2 5158 (74.6) 4691 (70.5) 3447 (62.7) 2519 (59.9) 2949 (59.4)
$30 kg/m
2, obese 1218 (17.6) 1359 (20.4) 1207 (22.0) 1090 (25.9) 1270 (25.6)
Missing* 534 (7.7) 606 (9.1) 843 (15.3) 593 (14.1) 745 (15.0)
Social class, n (%)
I, professional 297 (4.3) 280 (4.2) 316 (5.7) 225 (5.4) 277 (5.6)
II, managerial 1644 (23.8) 1696 (25.5) 1646 (29.9) 1232 (29.3) 1670 (33.6)
IIINM, skilled non-manual 1534 (22.2) 1404 (21.1) 1125 (20.5) 889 (21.2) 1011 (20.4)
IIIM, skilled manual 1424 (20.6) 1348 (20.3) 984 (17.9) 773 (18.4) 839 (16.9)
IV, semi-skilled manual 1111 (16.1) 1177 (17.7) 939 (17.1) 703 (16.7) 794 (16.0)
V, unskilled manual 575 (8.3) 468 (7.0) 320 (5.8) 253 (6.0) 252 (5.1)
Other (armed forces, unknown) 325 (4.7) 283 (4.3) 167 (3.0) 127 (3.0) 121 (2.4)
Education, n (%)
Level, 3 degree level or above 1793 (25.9) 1727 (25.9) 1482 (27.0) 1177 (28.0) 1458 (29.4)
Level, 2 intermediate 1043 (15.1) 1209 (18.2) 1070 (19.5) 1046 (24.9) 1265 (25.5)
Level 1, end of compulsory schooling 1839 (26.6) 1723 (25.9) 1641 (29.9) 1156 (27.5) 1337 (26.9)
No qualiﬁcations 2226 (32.2) 1978 (29.7) 1274 (23.2) 802 (19.1) 888 (17.9)
Other qualiﬁcations or missing 9 (0.1) 19 (0.3) 30 (0.5) 21 (0.5) 16 (0.3)
Nurse sample size selected, n 6910 6656 5497 1193 1255
Declined nurse 306 (4.4) 387 (5.8) 867 (15.8) 278 (23.3) 275 (21.9)
Agreed to nurse visit but not completed 525 (7.6) 752 (11.3) 913 (16.6) 195 (16.3) 218 (17.4)
Agreed to nurse visit and completed 6079 (88.0) 5517 (82.9) 3717 (67.6) 720 (60.4) 762 (60.7)
*Missing for body mass index (BMI) included pregnant women.
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Cardiovascular biomarker patternsTable 2 Characteristics of the 1995, 1998, 2003, 2008 and 2009 Scottish Health Surveys: nurse samples restricted to
25e64-year old respondents (unweighted data)
Scottish Health Survey
1995 1998 2003 2008 2009
Nurse sample size, n 6079 5517 3717 720 762
Mean age (SD) 43.4 (11.5) 44.1 (11.2) 45.9 (10.8) 46.5 (10.9) 46.3 (11.1)
Gender, n (%)
Male 2703 (44.5) 2479 (44.9) 1614 (43.4) 325 (45.1) 315 (41.3)
Female 3376 (55.5) 3038 (55.1) 2103 (51.5) 395 (54.9) 447 (58.7)
Waist circumference, n (%)
M <102; W <88 cm 4697 (77.3) 4035 (73.1) 2337 (62.9) 410 (56.9) 428 (56.2)
M $102; W $88 cm 1215 (20.0) 1374 (24.9) 1237 (33.3) 296 (41.1) 319 (41.9)
Missing 167 (2.7) 108 (2.0) 143 (3.8) 14 (1.9) 15 (2.0)
Waistehip ratio, n (%)
M <1.0; W <0.85 5052 (83.1) 4569 (82.8) 2697 (72.6) 507 (70.4) 523 (68.6)
M $1.0; W $0.85 831 (13.7) 835 (15.1) 868 (23.4) 199 (27.6) 224 (29.4)
Missing 196 (3.2) 113 (2.0) 152 (4.1) 14 (1.9) 15 (2.0)
Hypertension* (uncontrolled), n (%)
SBP <140, DBP<90 mm Hg 4145 (68.2) 3646 (66.1) 2326 (62.6) 484 (67.2) 507 (66.5)
SBP $140, DBP$90 mm Hg 845 (13.9) 744 (13.5) 681 (18.3) 130 (18.1) 144 (18.9)
Missing 1089 (17.9) 1127 (20.4) 710 (19.1) 106 (14.7) 111 (14.6)
Blood sample, n (%)
Yes 5498 (90.4) 4660 (84.5) 2984 (80.3) 607 (84.3) 618 (81.1)
Nodrefused 315 (5.2) 394 (7.1) 379 (10.2) 53 (7.4) 71 (9.3)
Missingy 266 (1.7) 463 (8.4) 355 (9.5) 60 (8.3) 73 (9.6)
Total cholesterol, n (%)z
<5.0 mmol 1267 (20.8) 1458 (26.4) 755 (20.3) 182 (25.3) 175 (23.0)
$5.0 mmol/l 4184 (68.8) 3124 (56.6) 2115 (56.9) 400 (55.6) 404 (53.0)
Missing 628 (10.3) 935 (16.9) 847 (22.8) 138 (19.2) 183 (24.0)
HDL cholesterol, n (%)x
M $1.0; W $1.2 mmol/l 4574 (75.2) 3755 (68.1) 2515 (67.7) 484 (67.2) 486 (63.8)
M <1.0; W <1.2 mmol/l 789 (13.0) 716 (13.0) 200 (5.4) 41 (5.7) 37 (4.9)
Missing 716 (11.8) 1046 (19.0) 1002 (27.0) 195 (27.1) 239 (31.4)
Total cholesterol: HDL cholesterol ratio, n (%)zx
<4.5 3272 (53.8) 2957 (53.6) 1910 (51.4) 389 (54.0) 385 (50.5)
$4.5 2091 (34.4) 1513 (27.4) 804 (21.6) 136 (18.9) 138 (18.1)
Missing 716 (11.8) 1047 (19.0) 1003 (27.0) 195 (27.1) 239 (31.4)
Fibrinogen, n (%){
Four quintiles e 3399 (61.6) 2028 (54.6) 388 (53.9) 405 (53.1)
Highest quintile e 800 (14.5) 473 (12.7) 102 (14.2) 82 (10.8)
Missing 1318 (23.9) 1216 (32.7) 230 (31.9) 275 (36.1)
C reactive protein, n (%)**
Four quintiles e 3573 (64.8) 2288 (61.6) 462 (64.2) 475 (62.3)
Highest quintile e 937 (17.0) 570 (15.3) 120 (16.7) 104 (13.6)
Missing 1007 (18.3) 859 (23.1) 138 (19.2) 183 (24.0)
Social class, n (%)
I, professional 265 (4.4) 228 (4.1) 221 (5.9) 38 (5.3) 46 (6.0)
II, managerial 1481 (24.4) 1427 (25.9) 1138 (30.6) 238 (33.1) 291 (38.2)
IIINM, skilled non-manual 1356 (22.3) 1187 (21.5) 776 (20.9) 149 (20.7) 155 (20.3)
IIIM, skilled manual 1261 (20.7) 1120 (20.3) 643 (17.3) 132 (18.3) 112 (14.7)
IV, semi-skilled manual 965 (15.9) 971 (17.6) 640 (17.2) 111 (15.4) 110 (14.4)
V, unskilled manual 488 (8.0) 381 (6.9) 207 (5.6) 36 (5.0) 37 (4.9)
Other (armed forces, unknown) 263 (4.3) 203 (3.7) 92 (2.5) 16 (2.2) 11 (1.4)
Continued
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Cardiovascular biomarker patternscoefﬁcient for the relationship between the prevalence
of each risk factor in each socioeconomic category and
the hierarchical ranking of each socioeconomic group
category on the social scale.
25 It can be interpreted as the
absolute change in health level when an individual goes
from the highest status to the lowest status in the social
hierarchy. In this context, a positive SII indicates that
there is higher prevalence of an adverse CVD risk factor
in the most disadvantaged compared with the least
disadvantaged in the socioeconomic hierarchy. A posi-
tive SII is therefore bad from a public health perspective.
Time trends for prevalence and the SIIs were assessed
using generalised linear regression. For the aggregated
2008/2009 data sets, the year was taken as 2008.5. All
analyses were performed using SAS V.9.2 (SAS Institute
Inc.), and statistical signiﬁcance was taken as p<0.05.
Sensitivity analyses
Individuals taking drugs affecting blood pressure or
lipid-lowering drugs were, respectively, excluded from
analyses involving hypertension and hyper-
cholesterolaemia. Also a deﬁnition of hypertension that
included respondents on drugs prescribed for high
blood pressure, irrespective of measurements, was
investigated (1998 onwards). Similarly, the effect of
including individuals taking lipid-lowering drugs in the
high-risk total cholesterol group was explored. The
proportion of individuals taking either drugs prescribed
for hypertension or lipid-lowering drugs was also inves-
tigated. Limited within-survey response analyses were
undertaken by comparing individuals that did not
complete the nurse interview or give a blood sample with
those that did comply with these requests; details of
analyses and results are provided in section 3 of the
supplementary information.
RESULTS
The participants’ mean age increased across the ﬁve
surveys, from 43.3 years in 1995 to 45.6 years in 2009
(table 1). The proportion of women was greater than
that of men in all the surveys (tables 1 and 2). Over time,
the population distribution shifted according to both
socioeconomic measures. In general, the proportion of
individuals in the ‘upper’ strata (eg, managerial class or
level 3 qualiﬁcations) increased compared with those in
the ‘lower’ strata (eg, unskilled class or no qualiﬁca-
tions). Those that did not complete a nurse interview or
a blood sample collection were more likely to be younger
and to be smokers in almost all the surveys (supple-
mentary tables 11e20). In the majority of the surveys,
those from a lower socioeconomic background were less
likely to have participated in later stages of the survey,
particularly for the blood sample.
Overall, for individuals with data on education, the
prevalence of obesity according to BMI increased by
0.7% per year (p<0.001) for men and 0.6% per year
(p<0.001) for women (table 3). The fastest rate of
increase was among unqualiﬁed men (0.9% per year,
p¼0.02) reaching a prevalence of 34.6% (95% CI 28.1%
to 41.1%) in 2009. An educational differential was
maintained in all the surveys; in 2009, the SII was 12.4
(p¼0.08). The ﬁndings were similar for women; in 2009,
those with no qualiﬁcations had the highest obesity
prevalence (34.9%, 27.5% to 42.3%) and the SII was 17.4
(p¼0.004). There were social class inequalities in obesity
among women, although there was an overall decline in
the SII from 1995 ( 0.4, p¼0.11)(table 4), while they
were relatively small for men.
As for BMI, there were signiﬁcant, or borderline
signiﬁcant, increases in the prevalence of excess
adiposity in terms of both WC and WHR (tables 3 and 4).
The proportion of men with excessive WHR was much
lower than the proportions with extreme BMI or WC. In
1995, the three anthropometric measures yielded similar
proportions of women with excess adiposity; however, by
2008/2009, a greater proportion had extreme values
according to WC and WHR than BMI. Large educational
inequalities existed for men and women for both WC
Table 2 Continued
Scottish Health Survey
1995 1998 2003 2008 2009
Education, n (%)
Level 3, degree level or above 1610 (26.5) 1441 (26.1) 1072 (28.8) 223 (31.0) 248 (32.5)
Level 2, intermediate 925 (15.2) 1023 (18.5) 750 (20.2) 183 (25.4) 203 (26.6)
Level 1, end of
compulsory schooling
1644 (27.0) 1432 (26.0) 1084 (29.2) 185 (25.7) 185 (24.3)
No qualiﬁcations 1894 (31.2) 1614 (29.3) 808 (21.7) 129 (17.9) 125 (16.4)
Other qualiﬁcations or missing 6 (0.1) 7 (0.1) 3 (0.1) e 1 (0.1)
*1995 and 1998 blood pressure readings were taken using Dinamap monitors and then converted to Omron monitor readings.
yReasons for a missing blood sample included failed collection, pregnancy or a clotting disorder.
zIn 1995, a different laboratory completed analyses. Different analysers were used but methods and reference standards were the same.
xDetermined in 1995 and 1998 using a different method, not comparable to 2003 and 2008/2009.
{Thresholds for highest quintile of plasma ﬁbrinogen concentration 1998: M >3.1 g/l, W >3.3 g/l; 2003: M >3.3 g/l, W >3.6 g/l; 2008/2009:
M >3.4 g/l, W >3.6 g/l.
**Thresholds for highest quintile of serum C reactive protein concentration 1998: M >3.4 mg/l, W >4.3 mg/l; 2003: M>3.5 mg/l, W >4.8 mg/l;
2008/2009: M >3.71 mg/l, W >4.80 mg/l. Pregnant women were excluded from all measurements and the blood sample.
DBP, diastolic blood pressure; HDL, high-density lipoprotein; M, manual; M, men; NM, non-manual; SBP, systolic blood pressure; W, women.
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Cardiovascular biomarker patternsand WHR. Over half of unqualiﬁed women had an
excessive WC (52.6%, 43.5% to 61.6%) and WHR
(56.4%, 47.2% to 65.7%) in 2008/2009. For women,
there was a signiﬁcant increase in the WHR SII across
education of 1.1 per year (p<0.001). There were also
social class inequalities in WC and WHR (table 4).
Overall prevalence of hypertension (uncontrolled) in
both sexes did not change signiﬁcantly over time,
although the trend was upwards (table 5). Prevalences
generally increased between 1998 and 2003, coinciding
with the change from predicted to actual Omron read-
ings. Socioeconomic inequalities in hypertension were
relatively small with the exception of those for social
class among men in 2008/2009 (SII¼13.9, p¼0.05)
(table 5). The larger inequalities partly reﬂect an
increase in prevalence of 1.1% per year (p¼0.01) among
unskilled men from 1995. Sensitivity analyses, excluding
respondents taking drugs affecting blood pressure or
including those taking drugs prescribed for hyperten-
sion, identiﬁed similar socioeconomic patterns (supple-
mentary tables 3 and 4). The proportion of respondents
taking drugs prescribed for hypertension increased
across the surveys with inequalities widening among
men, those from lower in the hierarchy having a greater
increase in uptake (supplementary tables 9 and 10).
Hypercholesterolaemia declined across the surveys:
from 1995 to 2008/2009, among those with educational
information, the prevalence decreased from 79.6%
(78.1% to 81.1%) to 63.8% (59.9% to 67.8%) for men
and from 74.1% (72.6% to 75.7%) to 66.3% (62.6% to
70.0%) for women (table 6). For both education and
social class, inequalities were minimal for men except by
education in 2008/2009. According to education, in the
ﬁrst three surveys, positive SIIs existed for women but in
2008/2009, the SII was  16.9 (p¼0.23), while for social
class, SIIs were generally small and positive (table 7).
Sensitivity analyses, excluding those on lipid-lowering
drugs or including them in the high-risk hyper-
cholesterolaemia group, had minimal impact on esti-
mates until the 2008/2009 survey where prevalences
estimates were elevated, particularly among men
(supplementary tables 5 and 6). The prevalence of
individuals taking lipid-lowering drugs increased across
the surveys while inequalities in uptake existed, with
educational inequalities widening (supplementary tables
9 and 10).
There was minimal change in the prevalence of low
HDL cholesterol between comparable surveys: namely
1995e1998 (supplementary tables 1 and 2) and 2003 to
2008/2009 (tables 6 and 7). There were signiﬁcant
educational inequalities for women in all surveys, in
2008/2009 the SII¼11.9 (p¼0.01) (table 6). Absolute
inequalities for men were generally smaller than in
women and in the case of social class were not consis-
tent. The proportion with high total cholesterol: HDL
cholesterol ratio decreased between comparable surveys
(supplementary tables 7 and 8). Strong inequalities
existed for women, while for men they were minimal.
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Cardiovascular biomarker patternsThe threshold ﬁbrinogen plasma concentration for
the upper quintile increased from 3.1 g/l in 1998 to
3.4 g/l in 2008/2009 for men and from 3.3 to 3.6 g/l for
women (tables 8 and 9). In 2008/2009, the threshold C
reactive protein serum concentration for the highest
quintile had increased to 3.71 mg/l for men and
4.80 mg/l for women (tables 8 and 9). For both
inﬂammatory risk markers, socioeconomic inequalities
existed that appeared greater in magnitude for men
than for women.
DISCUSSION
In Scotland, between 1995 and 2009, the changes in the
prevalence of three major risk factors for CVD present
a mixed story. Overall, prevalences have increased for
obesity (including central obesity), stagnated for hyper-
tension and decreased for hypercholesterolaemia. Many
of the biomarkers considered in this study had socio-
economic gradients that persisted throughout the
surveys. Considering this intransigence (with the excep-
tion of total cholesterol), it is perhaps not surprising that
behavioural risk factors have also changed little over the
same period in Scotland.
13
Consistent with the rest of the developed world the
Scottish population is becoming more obese.
26 The
larger increase in the prevalence of women with exces-
sive WC and WHR could suggest that the rise in obesity
among women has been particularly manifested as an
increase in central adiposity. For all three measures of
adiposity, absolute inequalities existed for both genders.
However, there were some inconsistencies by social class,
particularly for men. Greater inequalities for women
have been observed elsewhere.
27e30 The inequalities
remained unchanged over time, even widening for
women by WHR when stratiﬁed by education, similar to
ﬁndings in other European countries.
27 28 It should be
noted that for all the biomarkers considered in this
study, precise comparison with other studies is difﬁcult
because of different deﬁnitions, sample demographics
and study design.
An overall declining trend in mean systolic blood
pressure in the developed world, and in particular
Western Europe, has been identiﬁed.
31 In contrast,
although not directly comparable, our study identiﬁed
that the prevalence of hypertension remained relatively
static, with the hint of an increase, in Scotland. Levelling
of declines, or even an increase in the case of England,
have been identiﬁed in other countries over similar time
periods.
32e34 Inequalities have been reported for blood
pressure in other countries
32 35 and in the past for
Scotland among just women.
36 The static trend in Scot-
land may be in part a consequence of improved hyper-
tension management and medication, as in England,
34
along with reduced behavioural risk factors such as
increased physical activity and reduced discretional salt
use
13 being counteracted by increased obesity trends and
consumption of high salt content processed foods.
37
The good news of a modest decline in hyper-
cholesterolaemia in this study concurs with ﬁndings for
the developed world.
38 This is tempered by the stark fact
that in 2008/2009, the majority of respondents still had
excessive serum concentrations of total cholesterol.
Inequalities existed for women but these were less
apparentby2008/2009,whileformen,therewerelimited
social gradients. A lack of socioeconomic inequalities
for total cholesterol is a common ﬁnding.
32 33 A social
class differential has been reported for women for
hypercholesterolaemia in Scotland in the past
36 and
elsewhere in the UK.
39 Whereas historically for men in
Scotland, high cholesterol has been associated with non-
manual social class.
36 The decline in hyper-
cholesterolaemia prevalence is probably due to changes
inhealthbehaviours,for example,adecreasein saturated
fats consumption, along with the increased use of lipid-
lowering drugs over the surveys, their use being more
prevalent in more disadvantaged groups, particularly in
the 2008/2009 surveys.
The proportion with low HDL cholesterol concentra-
tion changed little between 2003 and 2008/2009. Within
each of the survey years, stronger social gradients existed
for women than for men with the disadvantaged having
a higher prevalence of low HDL cholesterol. Socioeco-
nomic gradients in this direction have been identiﬁed
for men and women,
40 just women
41 42 and appeared to
be absent for both sexes.
30 Elevated levels of C reactive
protein and ﬁbrinogen are associated with an increased
risk of CHD but are considered to be markers as they are
unlikely to be causal.
43 44 The absence of deﬁned clinical
thresholds indicating higher risk of CHD, plus skewed
distributions, prompted the use of upper quintiles; some
have considered this to represent ‘high risk’.
45 The
threshold demarking the upper quintile was always
higher for women, as seen in other studies,
46 and the
increase for both genders across the surveys would imply
a shift to the right for at least some of the population.
Much of the social gradient in these inﬂammatory
markers, as seen in this study, can be explained by risk
factors such as smoking, adiposity, cholesterol and
physical activity.
46e48 These risk factors are socially
patterned in the SHeSs, although the latter two princi-
pally for women.
13
One of this study’s strengths is the use of data from
nationally representative surveys. We also recognise
a number of limitations. Only individuals living in
private households were surveyed, and the declining
response levels in these surveys are of concern, possibly
introducing bias. This problem is common across surveys
in general. The clustered design of the sampling in this
study will lead to larger standard errors than those from
a simple random sample of the same size because
members of a cluster are more likely to resemble one
another. Nevertheless, the effect of clustering was
reduced as a high percentage of all possible postcode
sectors were included in the SHeSs. A switch to sampling
multiple adults within households from 2003 probably
Hotchkiss JW, Davies CA, Gray L, et al. BMJ Open 2012;2:e000771. doi:10.1136/bmjopen-2011-000771 13
Cardiovascular biomarker patternsT
a
b
l
e
8
G
e
n
d
e
r
-
s
p
e
c
i
ﬁ
c
,
a
g
e
-
s
t
a
n
d
a
r
d
i
s
e
d
p
r
e
v
a
l
e
n
c
e
s
f
o
r
e
l
e
v
a
t
e
d
p
l
a
s
m
a
ﬁ
b
r
i
n
o
g
e
n
a
n
d
s
e
r
u
m
C
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
c
o
n
c
e
n
t
r
a
t
i
o
n
s
i
n
ﬁ
v
e
S
c
o
t
t
i
s
h
H
e
a
l
t
h
S
u
r
v
e
y
s
1
9
9
5
,
1
9
9
8
,
2
0
0
3
a
n
d
2
0
0
8
/
2
0
0
9
s
t
r
a
t
i
ﬁ
e
d
b
y
h
i
g
h
e
s
t
e
d
u
c
a
t
i
o
n
a
l
q
u
a
l
i
ﬁ
c
a
t
i
o
n
a
c
h
i
e
v
e
d
M
e
n
W
o
m
e
n
P
r
o
p
o
r
t
i
o
n
i
n
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
%
)
(
9
5
%
C
I
)
T
r
e
n
d
(
p
v
a
l
u
e
)
P
r
o
p
o
r
t
i
o
n
i
n
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
%
)
(
9
5
%
C
I
)
T
r
e
n
d
(
p
v
a
l
u
e
)
1
9
9
5
1
9
9
8
2
0
0
3
2
0
0
8
/
2
0
0
9
*
1
9
9
5
1
9
9
8
2
0
0
3
2
0
0
8
/
2
0
0
9
*
F
i
b
r
i
n
o
g
e
n
T
h
r
e
s
h
o
l
d
f
o
r
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
g
/
l
)
y
>
3
.
1
0
>
3
.
3
0
>
3
.
4
0
>
3
.
3
0
>
3
.
6
0
>
3
.
6
0
A
l
l
e
1
8
.
6
(
1
7
.
0
t
o
2
0
.
2
)
1
8
.
4
(
1
6
.
2
t
o
2
0
.
6
)
1
9
.
0
(
1
5
.
5
t
o
2
2
.
5
)
0
.
0
(
0
.
5
2
)
e
1
8
.
1
(
1
6
.
4
t
o
1
9
.
7
)
1
7
.
9
(
1
5
.
8
t
o
2
0
.
1
)
1
8
.
9
(
1
5
.
4
t
o
2
2
.
3
)
0
.
1
(
0
.
4
0
)
L
e
v
e
l
3
e
9
.
9
(
6
.
9
t
o
1
2
.
9
)
1
4
.
2
(
1
0
.
4
t
o
1
8
.
0
)
1
2
.
9
(
7
.
6
t
o
1
8
.
3
)
0
.
3
(
0
.
5
4
)
e
1
6
.
5
(
1
3
.
7
t
o
1
9
.
3
)
1
5
.
5
(
1
1
.
7
t
o
1
9
.
3
)
1
2
.
3
(
7
.
3
t
o
1
7
.
3
)
 
0
.
4
(
0
.
1
7
)
L
e
v
e
l
2
e
1
8
.
7
(
1
5
.
2
t
o
2
2
.
1
)
1
8
.
0
(
1
2
.
7
t
o
2
3
.
3
)
1
8
.
7
(
1
1
.
5
t
o
2
5
.
9
)
0
.
0
(
0
.
9
4
)
e
1
4
.
5
(
9
.
1
t
o
1
9
.
8
)
1
2
.
7
(
8
.
1
t
o
1
7
.
4
)
1
8
.
8
(
1
1
.
9
t
o
2
5
.
7
)
0
.
4
(
0
.
5
0
)
L
e
v
e
l
1
e
1
9
.
6
(
1
6
.
6
t
o
2
2
.
7
)
1
9
.
7
(
1
5
.
7
t
o
2
3
.
7
)
2
2
.
7
(
1
5
.
4
t
o
3
0
.
1
)
0
.
3
(
0
.
3
1
)
e
1
9
.
1
(
1
5
.
3
t
o
2
2
.
9
)
2
1
.
0
(
1
6
.
8
t
o
2
5
.
3
)
2
7
.
0
(
1
8
.
8
t
o
3
5
.
3
)
0
.
8
(
0
.
1
6
)
N
o
q
u
a
l
i
ﬁ
c
a
t
i
o
n
s
e
2
4
.
9
(
2
1
.
0
t
o
2
8
.
9
)
2
1
.
1
(
1
5
.
9
t
o
2
6
.
3
)
2
7
.
5
(
1
4
.
9
t
o
4
0
.
1
)
0
.
3
(
0
.
7
2
)
e
2
0
.
4
(
1
7
.
1
t
o
2
3
.
7
)
2
0
.
1
(
1
4
.
8
t
o
2
5
.
4
)
2
0
.
3
(
1
1
.
8
t
o
2
8
.
8
)
0
.
0
(
0
.
8
4
)
S
I
I
(
p
v
a
l
u
e
)
1
6
.
9
(
0
.
0
6
)
9
.
2
(
0
.
0
3
)
1
7
.
9
(
0
.
0
0
4
)
0
.
1
(
0
.
9
1
)
6
.
4
(
0
.
1
7
)
8
.
7
(
0
.
2
7
)
1
6
.
3
(
0
.
1
8
)
1
.
0
(
0
.
1
7
)
C
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
T
h
r
e
s
h
o
l
d
f
o
r
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
m
g
/
l
)
>
3
.
4
0
>
3
.
5
0
>
3
.
7
1
>
4
.
3
0
>
4
.
8
0
>
4
.
8
0
A
l
l
e
1
9
.
9
(
1
8
.
3
t
o
2
1
.
5
)
1
9
.
8
(
1
7
.
6
t
o
2
1
.
9
)
1
8
.
8
(
1
5
.
7
t
o
2
1
.
9
)
 
0
.
1
(
0
.
2
3
)
e
2
0
.
0
(
1
8
.
3
t
o
2
1
.
6
)
1
9
.
6
(
1
7
.
5
t
o
2
1
.
6
)
1
9
.
6
(
1
6
.
3
t
o
2
2
.
9
)
0
.
0
(
0
.
4
2
)
L
e
v
e
l
3
e
1
3
.
0
(
9
.
9
t
o
1
6
.
1
)
1
6
.
6
(
1
2
.
9
t
o
2
0
.
3
)
1
1
.
9
(
7
.
3
t
o
1
6
.
6
)
 
0
.
1
(
0
.
8
4
)
e
1
5
.
8
(
1
3
.
1
t
o
1
8
.
6
)
1
4
.
7
(
1
1
.
2
t
o
1
8
.
2
)
1
5
.
2
(
1
0
.
0
t
o
2
0
.
4
)
 
0
.
1
(
0
.
6
2
)
L
e
v
e
l
2
e
1
9
.
4
(
1
5
.
9
t
o
2
2
.
9
)
1
5
.
9
(
1
1
.
1
t
o
2
0
.
8
)
1
8
.
7
(
1
2
.
4
t
o
2
4
.
9
)
 
0
.
1
(
0
.
8
9
)
e
1
9
.
3
(
1
3
.
2
t
o
2
5
.
3
)
1
4
.
0
(
9
.
7
t
o
1
8
.
4
)
1
7
.
3
(
1
1
.
1
t
o
2
3
.
5
)
 
0
.
2
(
0
.
7
7
)
L
e
v
e
l
1
e
2
0
.
8
(
1
7
.
9
t
o
2
3
.
7
)
1
9
.
8
(
1
6
.
1
t
o
2
3
.
5
)
2
3
.
0
(
1
6
.
7
t
o
2
9
.
2
)
0
.
2
(
0
.
5
2
)
e
2
1
.
8
(
1
8
.
0
t
o
2
5
.
7
)
2
3
.
3
(
1
9
.
1
t
o
2
7
.
4
)
2
4
.
3
(
1
6
.
8
t
o
3
1
.
8
)
0
.
2
(
0
.
0
8
)
N
o
q
u
a
l
i
ﬁ
c
a
t
i
o
n
s
e
2
7
.
4
(
2
3
.
2
t
o
3
1
.
5
)
2
5
.
8
(
1
9
.
9
t
o
3
1
.
7
)
3
2
.
9
(
2
1
.
0
t
o
4
4
.
9
)
0
.
5
(
0
.
4
5
)
e
2
3
.
1
(
1
9
.
7
t
o
2
6
.
4
)
2
3
.
6
(
1
8
.
1
t
o
2
9
.
2
)
2
3
.
2
(
1
5
.
6
t
o
3
0
.
7
)
0
.
0
(
0
.
9
2
)
S
I
I
(
p
v
a
l
u
e
)
1
6
.
4
(
0
.
0
4
)
1
1
.
0
(
0
.
1
2
)
2
4
.
2
(
0
.
0
3
)
0
.
8
(
0
.
5
9
)
1
0
.
7
(
0
.
0
3
)
1
4
.
3
(
0
.
1
1
)
1
2
.
9
(
0
.
0
8
)
0
.
2
(
0
.
6
1
)
E
d
u
c
a
t
i
o
n
a
l
q
u
a
l
i
ﬁ
c
a
t
i
o
n
c
a
t
e
g
o
r
i
e
s
¼
l
e
v
e
l
3
d
d
e
g
r
e
e
l
e
v
e
l
o
r
a
b
o
v
e
;
l
e
v
e
l
2
d
i
n
t
e
r
m
e
d
i
a
t
e
;
l
e
v
e
l
1
d
s
t
a
t
u
t
o
r
y
s
c
h
o
o
l
l
e
a
v
i
n
g
;
n
o
q
u
a
l
i
ﬁ
c
a
t
i
o
n
s
.
*
M
e
r
g
e
d
d
a
t
a
s
e
t
.
y
A
d
i
f
f
e
r
e
n
t
a
n
a
l
y
s
e
r
w
a
s
u
s
e
d
f
o
r
ﬁ
b
r
i
n
o
g
e
n
i
n
2
0
0
8
/
2
0
0
9
.
S
I
I
,
s
l
o
p
e
i
n
d
e
x
o
f
i
n
e
q
u
a
l
i
t
y
.
14 Hotchkiss JW, Davies CA, Gray L, et al. BMJ Open 2012;2:e000771. doi:10.1136/bmjopen-2011-000771
Cardiovascular biomarker patternsT
a
b
l
e
9
G
e
n
d
e
r
-
s
p
e
c
i
ﬁ
c
,
a
g
e
-
s
t
a
n
d
a
r
d
i
s
e
d
p
r
e
v
a
l
e
n
c
e
s
f
o
r
e
l
e
v
a
t
e
d
p
l
a
s
m
a
ﬁ
b
r
i
n
o
g
e
n
a
n
d
s
e
r
u
m
C
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
c
o
n
c
e
n
t
r
a
t
i
o
n
s
i
n
ﬁ
v
e
S
c
o
t
t
i
s
h
H
e
a
l
t
h
S
u
r
v
e
y
s
1
9
9
5
,
1
9
9
8
,
2
0
0
3
a
n
d
2
0
0
8
/
2
0
0
9
s
t
r
a
t
i
ﬁ
e
d
b
y
o
c
c
u
p
a
t
i
o
n
a
l
s
o
c
i
a
l
c
l
a
s
s
M
e
n
W
o
m
e
n
P
r
o
p
o
r
t
i
o
n
i
n
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
%
)
(
9
5
%
C
I
)
*
T
r
e
n
d
(
p
v
a
l
u
e
)
P
r
o
p
o
r
t
i
o
n
i
n
h
i
g
h
e
s
t
q
u
i
n
t
i
l
e
(
%
)
(
9
5
%
C
I
)
*
T
r
e
n
d
(
p
v
a
l
u
e
)
1
9
9
5
1
9
9
8
2
0
0
3
2
0
0
8
/
2
0
0
9
y
1
9
9
5
1
9
9
8
2
0
0
3
2
0
0
8
/
2
0
0
9
y
F
i
b
r
i
n
o
g
e
n
T
h
r
e
s
h
o
l
d
f
o
r
t
o
p
q
u
i
n
t
i
l
e
(
g
/
l
)
z
>
3
.
1
0
>
3
.
3
0
>
3
.
4
0
>
3
.
3
0
>
3
.
6
0
>
3
.
6
0
A
l
l
e
1
8
.
8
(
1
7
.
1
t
o
2
0
.
5
)
1
8
.
3
(
1
6
.
1
t
o
2
0
.
5
)
1
9
.
1
(
1
5
.
6
t
o
2
2
.
6
)
0
.
0
(
0
.
7
5
)
e
1
8
.
0
(
1
6
.
3
t
o
1
9
.
7
)
1
7
.
9
(
1
5
.
8
t
o
2
0
.
1
)
1
9
.
4
(
1
5
.
9
t
o
2
3
.
0
)
0
.
1
(
0
.
3
5
)
I
,
p
r
o
f
e
s
s
i
o
n
a
l
e
8
.
5
(
3
.
7
t
o
1
3
.
3
)
1
4
.
5
(
8
.
2
t
o
2
0
.
9
)
1
4
.
1
(
3
.
8
t
o
2
4
.
4
)
0
.
5
(
0
.
3
9
)
e
2
3
.
3
(
1
5
.
8
t
o
3
0
.
7
)
1
0
.
9
(
3
.
3
t
o
1
8
.
5
)
1
8
.
4
(
5
.
0
t
o
3
1
.
7
)
 
0
.
4
(
0
.
7
6
)
I
I
,
m
a
n
a
g
e
r
i
a
l
e
1
4
.
2
(
1
1
.
3
t
o
1
7
.
0
)
1
7
.
6
(
1
3
.
7
t
o
2
1
.
5
)
1
3
.
2
(
7
.
3
t
o
1
9
.
0
)
 
0
.
1
(
0
.
8
4
)
e
1
4
.
1
(
1
1
.
2
t
o
1
7
)
1
7
.
4
(
1
3
.
5
t
o
2
1
.
3
)
1
5
.
9
(
1
1
.
1
t
o
2
0
.
8
)
0
.
2
(
0
.
6
4
)
I
I
I
,
s
k
i
l
l
e
d
N
M
e
2
3
.
8
(
1
8
.
0
t
o
2
9
.
5
)
7
.
5
(
2
.
8
t
o
1
2
.
2
)
1
6
.
8
(
8
.
0
t
o
2
5
.
7
)
 
0
.
6
(
0
.
7
4
)
e
1
9
.
5
(
1
6
.
5
t
o
2
2
.
6
)
1
6
.
3
(
1
2
.
6
t
o
2
0
.
1
)
2
7
.
0
(
1
9
.
3
t
o
3
4
.
6
)
0
.
7
(
0
.
5
1
)
I
I
I
,
s
k
i
l
l
e
d
M
e
2
0
.
4
(
1
7
.
6
t
o
2
3
.
2
)
1
6
.
9
(
1
3
.
0
t
o
2
0
.
8
)
2
0
.
5
(
1
4
.
6
t
o
2
6
.
4
)
0
.
0
(
0
.
9
7
)
e
1
9
.
8
(
1
4
.
3
t
o
2
5
.
3
)
2
0
.
9
(
1
2
.
1
t
o
2
9
.
8
)
1
3
.
8
(
3
.
2
t
o
2
4
.
4
)
 
0
.
6
(
0
.
4
1
)
I
V
,
p
a
r
t
l
y
s
k
i
l
l
e
d
e
2
3
.
6
(
1
8
.
9
t
o
2
8
.
2
)
2
8
.
5
(
2
2
.
1
t
o
3
4
.
9
)
1
6
.
5
(
8
.
4
t
o
2
4
.
6
)
 
0
.
7
(
0
.
5
8
)
e
1
9
.
9
(
1
5
.
9
t
o
2
3
.
9
)
2
0
.
2
(
1
5
.
0
t
o
2
5
.
3
)
2
1
.
0
(
1
1
.
3
t
o
3
0
.
7
)
0
.
1
(
0
.
1
5
)
V
,
u
n
s
k
i
l
l
e
d
e
2
0
.
0
(
1
1
.
0
t
o
2
9
.
1
)
2
5
.
2
(
1
2
.
7
t
o
3
7
.
7
)
3
9
.
6
(
2
4
.
8
t
o
5
4
.
4
)
1
.
9
(
0
.
1
5
)
e
1
9
.
8
(
1
3
.
6
t
o
2
6
.
1
)
2
3
.
9
(
1
5
.
2
t
o
3
2
.
7
)
1
3
.
0
(
1
.
0
t
o
2
5
.
1
)
 
0
.
7
(
0
.
5
6
)
S
I
I
(
p
v
a
l
u
e
)
1
3
.
4
(
0
.
0
4
)
1
1
.
5
(
0
.
2
3
)
1
3
.
6
(
0
.
1
5
)
0
.
0
(
0
.
9
5
)
6
.
4
(
0
.
1
5
)
7
.
3
(
0
.
0
8
)
7
.
1
(
0
.
4
5
)
0
.
1
(
0
.
5
1
)
C
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
T
h
r
e
s
h
o
l
d
f
o
r
t
o
p
q
u
i
n
t
i
l
e
(
m
g
/
l
)
>
3
.
4
0
>
3
.
5
0
>
3
.
7
1
>
4
.
3
0
>
4
.
8
0
>
4
.
8
0
A
l
l
e
1
9
.
8
(
1
8
.
1
t
o
2
1
.
4
)
1
9
.
5
(
1
7
.
3
t
o
2
1
.
6
)
1
8
.
9
(
1
5
.
8
t
o
2
2
.
1
)
 
0
.
1
(
0
.
0
8
)
e
2
0
.
0
(
1
8
.
3
t
o
2
1
.
7
)
1
9
.
4
(
1
7
.
3
t
o
2
1
.
5
)
1
9
.
5
(
1
6
.
1
t
o
2
2
.
8
)
 
0
.
1
(
0
.
4
1
)
I
,
p
r
o
f
e
s
s
i
o
n
a
l
e
5
.
9
(
2
.
4
t
o
9
.
5
)
1
7
.
0
(
1
0
.
6
t
o
2
3
.
5
)
4
.
1
(
0
t
o
1
0
.
1
)
 
0
.
2
(
0
.
9
0
)
e
7
.
5
(
1
.
6
t
o
1
3
.
4
)
1
6
.
8
(
9
.
2
t
o
2
4
.
4
)
1
2
.
2
(
2
.
2
t
o
2
2
.
2
)
0
.
4
(
0
.
6
8
)
I
I
,
m
a
n
a
g
e
r
i
a
l
e
1
5
.
3
(
1
2
.
5
t
o
1
8
.
2
)
1
8
.
7
(
1
4
.
9
t
o
2
2
.
5
)
1
9
.
5
(
1
3
.
6
t
o
2
5
.
4
)
0
.
4
(
0
.
2
4
)
e
1
8
.
8
(
1
5
.
6
t
o
2
2
.
1
)
1
6
.
4
(
1
2
.
9
t
o
2
0
.
0
)
1
7
.
1
(
1
2
.
4
t
o
2
1
.
9
)
 
0
.
2
(
0
.
5
3
)
I
I
I
,
s
k
i
l
l
e
d
N
M
e
2
7
.
8
(
2
2
.
0
t
o
3
3
.
6
)
1
1
.
8
(
6
.
5
t
o
1
7
.
1
)
2
5
.
1
(
1
7
.
8
t
o
3
2
.
4
)
 
0
.
2
(
0
.
9
2
)
e
1
9
.
5
(
1
6
.
6
t
o
2
2
.
5
)
1
9
.
4
(
1
5
.
6
t
o
2
3
.
2
)
2
2
.
2
(
1
5
.
5
t
o
2
8
.
8
)
0
.
3
(
0
.
3
5
)
I
I
I
,
s
k
i
l
l
e
d
M
e
2
0
.
5
(
1
7
.
8
t
o
2
3
.
2
)
2
0
.
4
(
1
6
.
4
t
o
2
4
.
4
)
1
7
.
4
(
1
2
.
7
t
o
2
2
.
1
)
 
0
.
3
(
0
.
3
1
)
e
2
3
.
5
(
1
7
.
5
t
o
2
9
.
5
)
1
6
.
9
(
1
0
.
0
t
o
2
3
.
8
)
2
3
.
9
(
1
0
.
1
t
o
3
7
.
7
)
0
.
1
(
0
.
9
5
)
I
V
,
p
a
r
t
l
y
s
k
i
l
l
e
d
e
2
3
.
3
(
1
9
.
0
t
o
2
7
.
6
)
2
6
.
6
(
2
0
.
9
t
o
3
2
.
3
)
1
5
.
9
(
9
.
3
t
o
2
2
.
5
)
 
0
.
7
(
0
.
5
1
)
e
2
3
.
1
(
1
9
.
0
t
o
2
7
.
3
)
2
2
.
6
(
1
7
.
8
t
o
2
7
.
4
)
1
9
.
1
(
1
1
.
0
t
o
2
7
.
3
)
 
0
.
4
(
0
.
2
3
)
V
,
u
n
s
k
i
l
l
e
d
e
2
5
.
4
(
1
7
.
3
t
o
3
3
.
6
)
1
1
.
8
(
4
.
6
t
o
1
9
.
1
)
3
4
.
6
(
2
6
.
8
t
o
4
2
.
4
)
0
.
9
(
0
.
7
2
)
e
1
9
.
9
(
1
3
.
5
t
o
2
6
.
2
)
1
9
.
1
(
1
1
.
8
t
o
2
6
.
3
)
2
0
.
7
(
4
.
8
t
o
3
6
.
6
)
0
.
1
(
0
.
6
4
)
S
I
I
(
p
v
a
l
u
e
)
1
3
.
8
(
0
.
1
1
)
6
.
4
(
0
.
3
9
)
8
.
9
(
0
.
4
3
)
 
0
.
5
(
0
.
5
6
)
6
.
7
(
0
.
1
4
)
6
.
4
(
0
.
0
6
)
7
.
2
(
0
.
1
1
)
0
.
1
(
0
.
5
6
)
*
N
e
g
a
t
i
v
e
l
o
w
e
r
l
i
m
i
t
s
h
a
v
e
b
e
e
n
s
e
t
t
o
z
e
r
o
.
y
A
g
g
r
e
g
a
t
e
d
d
a
t
a
s
e
t
.
z
A
d
i
f
f
e
r
e
n
t
a
n
a
l
y
s
e
r
w
a
s
u
s
e
d
f
o
r
ﬁ
b
r
i
n
o
g
e
n
i
n
2
0
0
8
/
2
0
0
9
.
M
,
m
a
n
u
a
l
;
N
M
,
n
o
n
-
m
a
n
u
a
l
;
S
I
I
,
s
l
o
p
e
i
n
d
e
x
o
f
i
n
e
q
u
a
l
i
t
y
.
Hotchkiss JW, Davies CA, Gray L, et al. BMJ Open 2012;2:e000771. doi:10.1136/bmjopen-2011-000771 15
Cardiovascular biomarker patternscontributed to the decline as interviewers, after
enrolling one individual, may have been disincentivised
to pursue additional householders. Responders to
health examination surveys tend to be older, women, of
higher socioeconomic class and live healthier lifestyles.
49
The 2003 SHeS response was modestly skewed towards
those in less deprived areas.
50 A differential response
could lead to underestimates for most risk factors in the
lower socioeconomic groups, which suggests that true
inequalities are even greater than shown here, particu-
larly so for the most recent surveys.
Measurement error will have contributed to bias in
these analyses, as will the need to use predicted Omron
readings in the ﬁrst two surveys, the change in labora-
tories between 1995 and 1998 and the change in
ﬁbrinogen analyser between 2003 and 2008/2009.
However, the laboratories did use the same methods and
reference standards
16 and a high correlation has been
demonstrated between the different analysers.
51 These
limitations mean caution should be exercised when
interpreting prevalence trends but should not greatly
distort comparison of socioeconomic gradients. The
cross-sectional nature of these surveys does not capture
the lifelong burden of these risk markers within indi-
viduals, something that might have a considerable effect
on subsequent CVD. The increase over time in the
proportion of individuals with intermediate educational
qualiﬁcation may in part be a consequence of the subtle
changes in how educational achievement was deter-
mined across the surveys. These changes would have had
no impact on those with no qualiﬁcations or those with
the highest qualiﬁcations. A substantial component of
this increase is likely to be due to the rise in the school
staying on rates beyond compulsory education seen
since the 1970s in Scotland, where intermediate qualiﬁ-
cations would be achieved.
52
Inconsistency between the socioeconomic measures
highlights the beneﬁts of using both education and
social class and why they should not be used inter-
changeably.
53 54 There were sometimes apparent differ-
ences in inequalities depending on the measure used.
This may reﬂect the imperfection of these proxies as
measures of deprivation or it may demonstrate the
underlying heterogeneity of inequalities. Further
research would be valuable. Education reﬂects the long-
term inﬂuence of early life circumstance and not only
strongly determines an individual’s occupation, implying
some interdependency with social class, but also provides
the knowledge and life skills required to adopt healthier
lifestyles and maximise access to health resources.
55
Alternative indices such as area of deprivation, income
and NS-SEC were not consistently available across these
surveys. The use of NS-SEC-derived social class in the last
three surveys may have led to the misclassiﬁcation of
individuals. This, combined with the shift over time in
the composition of social classes and education, may
have led to some of the observed alterations in preva-
lence patterning. However, the SII accounts for the size
of the total population and changes in the distribution
of groupings making comparison over time possible.
One disadvantage of the SII is that it assumes a linear
relationship across the socioeconomic groups, some-
thing that may not necessarily be true. The low numbers
in the highest and lowest categories may have led to
potentially volatile individual estimates, especially in the
last two surveys. This was particularly a problem in the
2008/2009 surveys among men with no qualiﬁcations in
the younger age groups and this may have led to
imprecise age-standardised estimates for the lowest
educational category and care should be taken in their
interpretation.
Small changes in risk factor prevalence at the popu-
lation level could elicit substantial reductions in CHD
mortality.
56 57 Interventions to achieve such reductions
can centre on targeting high-risk individuals,
21 such as
the Keep Well programme
58 that is aimed at increasing
the rate of health improvement among high-risk indi-
viduals in the most deprived communities in Scotland. It
is too early to assess the impact of this programme on
biomarkers for CVD risk but its proposed expansion may
increase its effectiveness. Altering the health behaviours
of the whole population may have greater impact.
59 60 In
Scotland, there are a number of population-based
initiatives aimed at improving health behaviours and
consequently the biomarkers for CVD. These include
a tobacco control action plan,
61 a national physical
strategy,
62 healthy eating advice
63 and an action plan
relating to obesity.
64 If best practice interventions to
reduce classic risk factors were successful, most of the
absolute socioeconomic differences in CHD mortality
could be eliminated.
12 Elimination of relative inequal-
ities may require interventions to be targeted at the
socioeconomically disadvantaged (eg, the Keep Well
programme) or possibly by improving the circumstances
that create social inequality.
65 66
The increase in obesity prevalence is probably the
driver behind the rise in prevalence of diabetes reported
in Scotland over the same period.
13 In contrast, there
has not been a comparable increase in hypertension and
cholesterol prevalence, as might be expected. This
disassociation between obesity and other risk factors
could be due to interventions, such as medication,
ameliorating the adverse effects of obesity. It has been
shown that obese people in the current century,
although having higher risk factor levels than the non-
obese, have a lower prevalence of high cholesterol, high
blood pressure and smoking than obese individuals
40 years ago.
67 68 All the above could contribute to
explanations as to why overall CHD death rates have
continued to fall, despite increasing rates of obesity. If
obesity had not increased, there might have been
a decline in hypertension prevalence and a greater
reduction in hypercholesterolaemia. It is sobering to
consider that any gains in CHD mortality by reduction in
some risk factors may be offset by additional deaths from
obesity and diabetes. These trends could certainly
16 Hotchkiss JW, Davies CA, Gray L, et al. BMJ Open 2012;2:e000771. doi:10.1136/bmjopen-2011-000771
Cardiovascular biomarker patternscontribute to the observed levelling or slowing of the
decline among younger groups. The lack of progress in
reducing risk factor socioeconomic inequalities can only
ensure such differentials in CVD mortality will remain in
the Scottish population. More effective population-wide
policies are now urgently required.
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